Cardiovascular trials in diabetes: Past and present. Invited lecture of the XXXVth National Congress of the Spanish Society of Cardiology;Ensayos cardiovasculares en la diabetes: Pasado y presente. Conferencia especial del XXXV Congreso Nacional de la Sociedad Española de Cardiología

Revista Espanola de Cardiologia

Volumn 53, Issue 12, 2000, Pages 1553-1560

  Pyörälä, Kalevi ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Clinical trials; Coronary heart disease; Diabetes; Prevention; Prognosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; GEMFIBROZIL; GLUCOSE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; GLUCOSE BLOOD LEVEL; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; PROPHYLAXIS; RISK FACTOR; SMOKING CESSATION; VASCULAR DISEASE;

EID: 0343290358     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0300-8932(00)75279-1     Document Type: Conference Paper

References (12)

1. Haffner SM, Lehto S. Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetics subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-234.
2. Turner RC, Millus H, Neil HA, Stratton IM, Manley SE, Matthews DR et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study. Br Med J 1998; 316: 823-828.
3. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993; 153: 598-615.
4. Stamler J, Stamler R. Brown WV, Gotto AM, Greenland P. Grundy S et al. Serum cholesterol Doing the right thing. Circulation 1993; 88: 1954-1960.
5. Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI Study Group. Br Med J 1997; 314: 1512-1515.
6. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. Lancet 1998; 352: 837-853.
7. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A et al. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. Lancet 1999; 353: 611-616.
8. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
9. Tuomilehto J, Rastenyte D, Birkenhager WH, Thijs L, Antikainen R, Bulpitt CJ et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677-684.
10. Koskinen P, Mänttäri M, Manninen V. Huttunen JK, Heinonen OP, Frick MH. Coronary heart disease incidence in NIDDM patients in the Helsinki Heart Study. Diabetes Care 1992; 15: 820-825.
11. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA et al. Primary prevention of acute coronary events with lovastatin in men and woman with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998; 279: 1615-1622.
12. Collaborative overview of randomised trial of antiplatelet therapy. I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. Br Med J 1994; 308: 81-106.